tiakis Biotech AG
Clinical-stage biopharmaceutical company based in Kiel, Germany, focused on development of an investigational recombinant human protein therapeutic with anti-inflammatory and tissue-protective properties for indications with high unmet medical need (notably pulmonary arterial hypertension, prevention of postoperative inflammatory complications and acute inflammatory lung disease). The company conducts preclinical research, GLP-compliant testing, clinical development (Phase I to Phase II), and collaborates with CDMOs and academic partners to scale manufacturing and run clinical trials.
Industries
N/A
Products
Investigational recombinant human protease-inhibitor therapeutic (recombinant protein candidate)
Clinical-stage recombinant human protein therapeutic developed as an anti-inflammatory and tissue-protective agent; being developed for pulmonary arterial hypertension, prevention of postoperative inflammatory complications following major surgery, and treatment of severe inflammatory lung disease.
Investigational recombinant human protease-inhibitor therapeutic (recombinant protein candidate)
Clinical-stage recombinant human protein therapeutic developed as an anti-inflammatory and tissue-protective agent; being developed for pulmonary arterial hypertension, prevention of postoperative inflammatory complications following major surgery, and treatment of severe inflammatory lung disease.
Services
Collaborative development and licensing
Partnering for research collaborations, clinical program internationalization, regulatory support, market preparation, and licensing or co-development arrangements for biopharmaceutical candidates.
Collaborative development and licensing
Partnering for research collaborations, clinical program internationalization, regulatory support, market preparation, and licensing or co-development arrangements for biopharmaceutical candidates.
Expertise Areas
- Clinical trial management (Phase I–II)
- Biologics process development and scale-up
- Recombinant protein therapeutic development
- Preclinical translational research
Key Technologies
- Recombinant protein production
- Industrial-scale fermentation (stainless-steel bioreactors, up to 3,000 L)
- Rodent disease models (neonatal lung injury, PAH models)
- Pharmacokinetic assays